Perrigo Company plc PRGO R3KPHARMA
Company Overview
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Why Investors Should Care
Offers a dividend yield of 8.61%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $4.25B (-2.8% YoY); net profit $-1.43B.
- Trailing 12 Months Year-on-year growth — revenue -3.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.47% |
| 1 Year: | -3.20% |
Stock Price Performance
| 1 Year: | -34.56% |
| 6 Months: | +48.37% |
| 3 Months: | +28.17% |
| 1 Month: | +15.89% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross2d ago
- RSI (14)65.15 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 8.61%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 36.8% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRGO Perrigo Company plc R3KPHARMA | 14.58 | -1.19 | $2.02B | 8.61% | 4.16% | -48.75% | 2.47% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Apr 2016 | Jul 2016 | Oct 2016 | Dec 2016 | Apr 2017 | Jul 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Oct 2022 | Apr 2023 | Jul 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 1.19B | 1.24B | 1.23B | 1.28B | 1.22B | 1.19B | 1.13B | 1.20B | 1.17B | 1.15B | 1.19B | 1.32B | 1.08B | 948.80M | 1.00B | 1.29B | 1.01B | 981.10M | 1.04B | 1.07B | 1.12B | 1.10B | 1.18B | 1.19B | 1.12B | 1.08B | 1.07B | 1.09B | - | 1.04B | 1.06B | 1.04B | 1.11B | 969.20M | 1.02B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 651.60M | 693.40M | 666.20M | 747.40M | 643.70M | - |
| Gross Profit | 543.70M | 533.10M | 546.50M | 484.50M | 487.70M | 464.40M | 504.60M | 497.80M | 512.70M | 492.70M | 471.00M | 424.80M | 443.00M | 448.80M | 430.80M | 412.80M | 480.90M | 393.70M | 347.20M | 369.70M | 469.20M | 368.40M | 349.00M | 336.40M | 337.80M | 372.10M | 362.90M | 413.80M | 428.00M | 411.20M | 357.70M | 394.70M | 404.40M | - | 392.30M | 362.90M | 377.10M | 362.20M | 325.50M | 313.90M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 312.90M | 307.30M | 283.70M | 277.80M | 291.90M | - |
| Operating Income | - | -231.60M | 184.80M | -1.47B | - | 128.50M | 148.80M | 162.40M | - | 156.30M | 94.70M | -122.00M | - | 102.30M | 55.00M | 54.40M | - | 86.40M | 62.70M | 78.50M | - | 51.40M | -125.90M | 438.30M | 21.70M | -6.90M | 33.10M | 48.50M | 56.80M | 62.10M | -55.20M | -26.50M | 80.40M | - | 79.40M | 55.60M | 93.40M | 84.40M | 33.60M | 23.50M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 127.20M | 129.10M | 148.40M | -1.20B | -284.40M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.00M | 39.60M | 40.60M | 43.30M | 40.80M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.30M | 3.20M | 22.40M | -1.33B | -408.50M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.20M | 3.70M | 9.70M | 82.90M | -18.70M | - |
| Net Income | -218.40M | -529.20M | -534.30M | -1.59B | -1.36B | 71.60M | -69.60M | 44.50M | 73.10M | 80.80M | 36.20M | -67.50M | 81.50M | 63.90M | 9.00M | 92.20M | -19.00M | 106.40M | 60.60M | -154.60M | -175.00M | 38.10M | -57.70M | -58.90M | -2.40M | -65.10M | -49.40M | -3.00M | 8.40M | 14.20M | 2.00M | -108.40M | -21.00M | - | -6.40M | -8.40M | 7.50M | -1.42B | -398.60M | 74.50M |
| Diluted EPS | -1.51 | -3.70 | -3.73 | -11.10 | -9.48 | 0.50 | -0.49 | 0.31 | 0.52 | 0.57 | 0.26 | -0.49 | 0.60 | 0.47 | 0.07 | 0.67 | -0.14 | 0.77 | 0.44 | -1.12 | -1.29 | 0.28 | -0.43 | -0.44 | -0.02 | -0.48 | -0.37 | -0.02 | 0.06 | 0.10 | 0.01 | -0.79 | -0.15 | - | -0.05 | -0.06 | 0.05 | -10.22 | -2.87 | 0.53 |
| R&D Expense | - | 45.30M | 47.00M | 50.20M | - | 39.80M | 42.60M | 38.40M | - | 38.40M | 91.90M | 43.70M | - | 40.20M | 43.90M | 44.00M | - | 27.90M | 30.40M | 30.40M | - | 31.10M | 33.00M | 27.60M | 29.30M | 31.50M | 29.80M | 31.10M | 32.20M | 29.60M | 29.00M | 29.40M | 26.00M | - | 26.70M | 22.00M | 24.90M | - | 24.60M | 23.70M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.17B | 800.00K | 3.91B | 4.23B | 5.28B | 4.95B | 4.73B | 3.87B | 4.09B | - | 4.45B | 4.66B | 4.37B | 4.25B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 3.00B | 2.98B | 2.83B | 2.76B |
| Gross Profit | 1.10B | 1.28B | 1.45B | 1.64B | 2.05B | 1.98B | 1.83B | 1.43B | 1.49B | - | 1.46B | 1.68B | 1.54B | 1.49B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 1.33B | 1.40B | 1.23B | 1.18B |
| Operating Income | 569.20M | 679.10M | 571.40M | 672.50M | -2.00B | 598.20M | 236.50M | 174.70M | 265.20M | - | 121.40M | 284.10M | 311.90M | 312.80M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | 355.50M | 525.00M | 433.00M | -797.90M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 156.00M | 173.80M | 187.80M | 162.50M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -139.10M | -8.30M | -80.70M | -1.30B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | -8.20M | -3.90M | 80.00M | 104.40M |
| Net Income | 401.60M | 441.90M | 232.80M | 136.10M | -4.01B | 119.60M | 131.00M | 146.10M | -162.60M | - | -140.60M | -12.70M | -171.80M | -1.43B |
| Diluted EPS | 4.27 | 4.68 | 2.01 | 0.97 | -28.01 | 0.84 | 0.95 | 1.07 | -1.19 | - | -1.04 | -0.09 | -1.25 | -10.29 |
| R&D Expense | 105.80M | 115.20M | 152.50M | 187.80M | 184.00M | 167.70M | 218.60M | 119.20M | 121.70M | 122.00M | 123.10M | 122.50M | 112.20M | 95.40M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 5.34B | 13.88B | 19.59B | 19.35B | 13.87B | 11.63B | 10.98B | 11.30B | 11.49B | - | 11.02B | 10.81B | 9.65B | 8.54B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 2.72B | 2.83B | 2.48B | 2.80B |
| Cash & Equivalents | 310.10M | 602.50M | 779.90M | 799.50M | 785.60M | 417.80M | 622.30M | 678.70M | 551.10M | 354.30M | 631.50M | - | 600.70M | 751.30M | 558.80M | 531.60M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 1.15B | 1.14B | 1.08B | 1.15B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 697.10M | 739.60M | 642.30M | 612.80M |
| Total Liabilities | - | - | 3.02B | 5.16B | 8.89B | 9.24B | 7.91B | 5.46B | 5.32B | 5.50B | 5.83B | - | 6.18B | 6.04B | 5.33B | 5.60B |
| Current Liabilities | - | - | 749.40M | 1.07B | 1.75B | 2.55B | 1.84B | 1.44B | 1.54B | 1.34B | 1.38B | - | 1.11B | 1.59B | 1.04B | 1.01B |
| Long Term Debt | - | - | 1.93B | 3.06B | 4.97B | 4.97B | 5.22B | 3.27B | 3.05B | 3.37B | 3.53B | - | 4.07B | 3.63B | 3.58B | 3.60B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 4.32B | 4.07B | 3.62B | 3.64B |
| Total Equity | 1.53B | 1.85B | 2.33B | 8.72B | 10.70B | 10.11B | 5.96B | 6.17B | 5.67B | 5.80B | 5.66B | - | 4.84B | 4.77B | 4.32B | 2.94B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 134.70M | 135.51M | 136.43M | 137.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 513.40M | 553.80M | 633.00M | 855.20M | 654.90M | 698.90M | 593.00M | 387.80M | 636.20M | - | 307.30M | 405.50M | 362.90M | 238.50M |
| Investing Cash Flow | -684.10M | -947.80M | -1.64B | -2.30B | -175.00M | 2.34B | -126.80M | -596.10M | -187.80M | - | -1.96B | -77.50M | 78.80M | -75.40M |
| Financing Cash Flow | 458.70M | 577.20M | 1.03B | 1.52B | -268.70M | -3.00B | -571.90M | 1.80M | -181.10M | - | 421.60M | -187.20M | -611.00M | -220.50M |
| Capital Expenditure | -120.20M | -104.10M | -171.60M | -137.00M | -106.20M | -88.60M | -102.60M | -137.70M | -170.40M | - | -96.40M | -101.70M | -118.30M | -93.40M |
| Free Cash Flow | 393.20M | 449.70M | 461.40M | 718.20M | 548.70M | 610.30M | 490.40M | 250.10M | 465.80M | - | 210.90M | 303.80M | 244.60M | 145.10M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -1.23B | 140.80M | -169.30M | -57.40M |
| Share Buybacks | 8.20M | 0 | 0 | 0 | 0 | 191.50M | 400.00M | 0 | 164.20M | 0 | 0 | - | - | - |
| Dividends Paid | 29.00M | 33.00M | 46.10M | 64.80M | 83.20M | 91.10M | 104.90M | 112.40M | 123.90M | 129.60M | 142.40M | 149.70M | 152.50M | 159.30M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 34.5% | 160,000.0% | 37.1% | 38.9% | 38.9% | 40.0% | 38.7% | 37.0% | 36.6% | - | 32.7% | 36.1% | 35.3% | 35.1% |
| Operating Margin % | 17.9% | 84,887.5% | 14.6% | 15.9% | -37.9% | 12.1% | 5.0% | 4.5% | 6.5% | - | 2.7% | 6.1% | 7.1% | 7.4% |
| Net Margin % | 12.7% | 55,237.5% | 5.9% | 3.2% | -76.0% | 2.4% | 2.8% | 3.8% | -4.0% | - | -3.2% | -0.3% | -3.9% | -33.5% |
| ROE % | 21.7% | 19.0% | 2.7% | 1.3% | -67.4% | 1.9% | 2.3% | 2.5% | -2.9% | - | -2.9% | -0.3% | -4.0% | -48.6% |
| ROCE % | - | 14.8% | 4.5% | 3.8% | -16.6% | 5.9% | 2.5% | 1.8% | 2.6% | - | 1.2% | 3.1% | 3.6% | 4.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 16.36% | 22.70M | $307.85M |
| 2 | Neuberger Berman Group, LLC | 7.70% | 10.68M | $144.82M |
| 3 | Vanguard Portfolio Management LLC | 6.52% | 9.05M | $122.66M |
| 4 | Price (T.Rowe) Associates Inc | 6.27% | 8.70M | $117.98M |
| 5 | State Street Corporation | 6.15% | 8.53M | $115.65M |
| 6 | Fuller & Thaler Asset Management Inc. | 5.40% | 7.50M | $101.68M |
| 7 | Vanguard Capital Management LLC | 4.50% | 6.25M | $84.69M |
| 8 | Invesco Ltd. | 4.23% | 5.87M | $79.55M |
| 9 | Dimensional Fund Advisors LP | 3.94% | 5.47M | $74.13M |
| 10 | Menora Mivtachim Holdings Ltd. | 3.17% | 4.39M | $59.59M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRGO
Should Value Investors Buy Perrigo (PRGO) Stock? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOcG1JVEpIYS1MRHFEdHhnYXJONmxVRmJMekFWMkNGZGwyNy1DTHhyWmtRUGZRWUM4WURURjRDUEk3dHNaZmQ1VjdMN2ZqTXd3ZERjdE1jTFE4MU0wM1VUWE5kYTgybFlpUjZoQ1R4SXpxQ0R3aVVtbVJrelUwZ1ZoTG5Xak9Ld2xnTGl2RX…
Perrigo (PRGO) Stock Looks Undervalued Despite Weak Returns And Cash Flow Risk - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxNbHJfaThtSHpvOE11bXZwS2xKdUQxemVrZVRuQzZlUFJWUkNQd0MwdTh4c1l0c0RXaDBVbHhWUk1aWG9JSXVMWkl6N2FCSVJ3OVp4aVg3OFl0dUptUmNwTlBwMUlUNWdCU1REYWFEOGJKaXBxRnBzNGtrMHd5QVpfSGw1TU43R3pETm1yT2…
Should Value Investors Buy Perrigo (PRGO) Stock? - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOMFBoR0VsNEg5ZldXNmJMNTNkOWV2c0VOVXl2Z0dsTlA1MXlISzB0MENlbHMzWVJhSUdyVEFSb2pmaktlYkp0XzZjYUNNTG5lOVRvLUkzeUV6UElzeF9jQ0pKZzdPN1FyQ0RwWDBmVTlnQmRaN2VnNlpEcC1DQUtQMDFnQmQ0YTJGeUhVT2…
A Look at Perrigo Co PLC (PRGO) After 4.6% Gain -- GF Value $23. - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQUnBWZlp0cUVtSmxwb0V1TksyV0Q5Z1h0eGRPZ0oxNm01aVZ4cEJzRlRuVk8xZzd0dms2clJodGpMbTJDemlSNE9QY3VSM0lqRkJadS1pUmlWREE5c2VtaG5mQkVtTE5iQTZjSGhuX1RUcEJDNU1DSE43UWZPbTY4OGxkX1pKc1FoWTBzNE…
Perrigo (NYSE:PRGO) Stock Price Down 4.4% - Should You Sell? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNRzVJTnVYSjN4MlpQOEVLd0o0TkhKY2NKSVBNeTJJc2tfZnBzTTl3ZGFYaHJhX280UmFhNEU1dkJLUFhGUFBhWU5TQ0Z6VzNNcmtLT25ENEdUbUVpT0pwZzBTZ3RFNzNqeThBbkc4RU85VC1WamVPMU5Nc3Z6MHozMUVHbU5RUlMxcnRKZm…
Perrigo Stock (-7.7%): Weak 2026 Guidance and Restructuring Drive Sell-Off - Trefis
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPZF9YTUhpeDBHcTBqckdMTGlMS21DWFRIbzhQSmtDVGJMb3RQNzgxMHNJUHlHODJLWlEwUDFBVmpSY2RHYzlGSlR0UjNOdjd3WU05NklEV3Q2bkxEYmw5clk4LTg4Z01vMGNzU1BlSDRvUF9BY2dvZGJmSUZOY24wX0xyR01GNFRqRWdrRH…
PRGO — Frequently Asked Questions
What is the current share price of Perrigo Company plc (PRGO)?
As of 2026-09-19 21:16 PDT, Perrigo Company plc (PRGO) trades at $14.58 on NYSE. Its 52-week range is $8.83 to $23.06.
What is the market capitalisation of PRGO?
Perrigo Company plc (PRGO) has a market capitalisation of $2.02B on NYSE.
What is the P/E ratio of PRGO?
PRGO trades at a trailing price-to-earnings (P/E) ratio of -1.19. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.75.
Does PRGO pay a dividend?
Perrigo Company plc (PRGO) currently offers a dividend yield of 8.61%.
What is the return on equity (ROE) of PRGO?
PRGO has a return on equity (ROE) of -48.75%. Its return on capital employed (ROCE) is 4.16%.
Is PRGO a good stock to buy?
This page provides a data-driven analysis of Perrigo Company plc (PRGO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.